Treatment of respiratory tract infections with moxifloxacin: Results of postmarketing surveillance in China

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1509-1515

  Liu, L Y ^a   Landen, H ^b,c  

^a Respiratory Department   (China)

^b BAYER PHARMA AG   (Germany)

^c Post Marketing Surveillance   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OPEN STUDY; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RESPIRATORY TRACT INFECTION; TREATMENT DURATION;

ADULT; AGED; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; QUINOLINES; RESPIRATORY TRACT INFECTIONS;

EID: 34547732406     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01484.x     Document Type: Article

References (19)

1. Miravitlles M, Murio C, Guerrero T, Gisbert R DAFNE Study Group. Decisiones sobre Antibioticoterapia y Farmacoeconomia en la EPOC. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002 121 : 1449 55.
2. Halls GA. The management of infections and antibiotic therapy: a European survey. J Antimicrob Chemother 1993 31 : 985 1000.
3. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003 9 : 1 9.
4. Lonks JR, Garau J, Medeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002 50 (Suppl. S2 87 92.
5. Blondeau JM. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999 43 (Suppl. B 1 11.
6. Koch H, Landen H, Stauch K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice. Evidence from a post-marketing surveillance study of 1467 patients. Clin Drug Invest 2004 24 : 441 8.
7. Landen H, Bauer T. Efficacy, onset of action and tolerability of moxifloxacin in patients with community-acquired pneumonia. Results of a postmarketing surveillance study. Clin Drug Invest 2001 21 : 801 11.
8. Barth J, Landen H. Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbations of chronic bronchitis. Clin Drug Invest 2003 23 : 1 10.
9. Elies W, Landen H, Stauch K. Efficacy and tolerability of moxifloxacin in patients with sinusitis treated in general practice. Results of a post-marketing surveillance study. Clin Drug Invest 2004 24 : 431 9.
10. Wilson R, Kubin R, Ballin I et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999 44 : 501 13.
11. Kreis SR, Herrera N, Golzar N et al. A comparison of moxifloxacin and azithromycin in the treatment of acute exacerbations of chronic bronchitis. J Clin Outcomes Manag 2000 7 : 33 7.
12. DeAbate CA, Mathew CP, Warner JH et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000 94 : 1029 37.
13. Urueta J, Ariza J, De Brito A et al. Safety and efficacy of moxifloxacin vs. levofloxacin in the treatment of AECB [abstract]. Clin Microbiol Infect 2001 7 (Suppl. 1 168.
14. Fogarty C, Grossman C, Williams J et al. Efficacy and safety of moxifloxacin vs. clarithromycin for community-acquired pneumonia. Infect Med 1999 16 : 748 63.
15. Hoeffken G, Meyer HP, Winter J et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001 95 : 553 64.
16. Krasemann C, Meyer JM, Springsklee M et al. Moxifloxacin in Community-acquired-pneumonia - a Bacteriological and Clinical Meta-analysis. 9th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999 (Poster).
17. Siegert R, Gehanno P, Nikolaidis P et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12-8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000 94 : 337 44.
18. Rakkar S, Robers K, Towe BF et al. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001 55 : 309 15.
19. Klossek JM, Siegert R, Nikolaidis P, Arvis P, Leberre MA. Comparison of the efficacy and safety of moxifloxacin and trovafloxacin for the treatment of acute bacterial maxillary sinusitis in adults. J Laryngol Otol 2003 117 : 43 51.